MGP Database

New search | Record Overview | Ontology/Pathway Information | Domain Information | UniProt Annotations | Related Proteins
MGP002294

UniProt Annotations

Entry Information
Gene Namephosphoinositide-3-kinase, regulatory subunit 1 (alpha)
Protein EntryP85A_HUMAN
UniProt IDP27986
SpeciesHuman
Comments
Comment typeDescription
Alternative ProductsEvent=Alternative splicing; Named isoforms=5; Name=1; IsoId=P27986-1; Sequence=Displayed; Name=2; Synonyms=AS53; IsoId=P27986-2; Sequence=VSP_021842, VSP_021843; Name=3; Synonyms=p46; IsoId=P27986-3; Sequence=VSP_021841, VSP_021844; Name=4; Synonyms=p85I; IsoId=P27986-4; Sequence=VSP_021845; Name=5; IsoId=P27986-5; Sequence=VSP_045903; Note=No experimental confirmation available.;
DiseaseAgammaglobulinemia 7, autosomal recessive (AGM7) [MIM:615214]: A primary immunodeficiency characterized by profoundly low or absent serum antibodies and low or absent circulating B-cells due to an early block of B-cell development. Affected individuals develop severe infections in the first years of life. {ECO:0000269|PubMed:22351933}. Note=The disease is caused by mutations affecting the gene represented in this entry.
DiseaseImmunodeficiency 36 (IMD36) [MIM:616005]: A primary immunodeficiency characterized by impaired B-cell function, hypogammaglobulinemia and recurrent infections. {ECO:0000269|PubMed:25133428}. Note=The disease is caused by mutations affecting the gene represented in this entry.
DiseaseSHORT syndrome (SHORTS) [MIM:269880]: A rare, multisystem disease characterized by short stature, anomalies of the anterior chamber of the eye, characteristic facial features such as triangular facies, lack of facial fat, and hypoplastic nasal alae with overhanging columella, partial lipodystrophy, hernias, hyperextensibility, and delayed dentition. The clinical phenotype can include insulin resistance, nephrocalcinosis, and hearing deficits. Developmental milestones and cognition are normal. {ECO:0000269|PubMed:23810378, ECO:0000269|PubMed:23810379, ECO:0000269|PubMed:23810382}. Note=The disease is caused by mutations affecting the gene represented in this entry.
DomainThe SH3 domain mediates the binding to CBLB, and to HIV-1 Nef.
FunctionBinds to activated (phosphorylated) protein-Tyr kinases, through its SH2 domain, and acts as an adapter, mediating the association of the p110 catalytic unit to the plasma membrane. Necessary for the insulin-stimulated increase in glucose uptake and glycogen synthesis in insulin-sensitive tissues. Plays an important role in signaling in response to FGFR1, FGFR2, FGFR3, FGFR4, KITLG/SCF, KIT, PDGFRA and PDGFRB. Likewise, plays a role in ITGB2 signaling (PubMed:17626883, PubMed:19805105, PubMed:7518429). Modulates the cellular response to ER stress by promoting nuclear translocation of XBP1 isoform 2 in a ER stress- and/or insulin-dependent manner during metabolic overloading in the liver and hence plays a role in glucose tolerance improvement (PubMed:20348923). {ECO:0000269|PubMed:17626883, ECO:0000269|PubMed:19805105, ECO:0000269|PubMed:20348923, ECO:0000269|PubMed:7518429}.
InteractionQ8IZP0:ABI1; NbExp=8; IntAct=EBI-79464, EBI-375446; P42684:ABL2; NbExp=2; IntAct=EBI-79464, EBI-1102694; P10275:AR; NbExp=5; IntAct=EBI-79464, EBI-608057; P22681:CBL; NbExp=5; IntAct=EBI-79464, EBI-518228; P10747:CD28; NbExp=8; IntAct=EBI-79464, EBI-4314301; Q8IY22:CMIP; NbExp=2; IntAct=EBI-79464, EBI-7689652; P46108:CRK; NbExp=2; IntAct=EBI-79464, EBI-886; P46109:CRKL; NbExp=2; IntAct=EBI-79464, EBI-910; P16410:CTLA4; NbExp=3; IntAct=EBI-79464, EBI-1030991; Q9Y2H0:DLGAP4; NbExp=2; IntAct=EBI-79464, EBI-722139; P00533:EGFR; NbExp=5; IntAct=EBI-79464, EBI-297353; P04626:ERBB2; NbExp=11; IntAct=EBI-79464, EBI-641062; P21860:ERBB3; NbExp=40; IntAct=EBI-79464, EBI-720706; P03372:ESR1; NbExp=6; IntAct=EBI-79464, EBI-78473; P48023:FASLG; NbExp=2; IntAct=EBI-79464, EBI-495538; P11362:FGFR1; NbExp=5; IntAct=EBI-79464, EBI-1028277; P17948:FLT1; NbExp=2; IntAct=EBI-79464, EBI-1026718; P36888:FLT3; NbExp=2; IntAct=EBI-79464, EBI-3946257; Q13480:GAB1; NbExp=33; IntAct=EBI-79464, EBI-517684; P62993:GRB2; NbExp=3; IntAct=EBI-79464, EBI-401755; P42858:HTT; NbExp=7; IntAct=EBI-79464, EBI-466029; P08069:IGF1R; NbExp=4; IntAct=EBI-79464, EBI-475981; P06213:INSR; NbExp=3; IntAct=EBI-79464, EBI-475899; P35568:IRS1; NbExp=12; IntAct=EBI-79464, EBI-517592; P35570:Irs1 (xeno); NbExp=2; IntAct=EBI-79464, EBI-520230; Q9Y4H2:IRS2; NbExp=2; IntAct=EBI-79464, EBI-1049582; P10721:KIT; NbExp=19; IntAct=EBI-79464, EBI-1379503; Q86VI4-3:LAPTM4B; NbExp=2; IntAct=EBI-79464, EBI-3267286; O43561:LAT; NbExp=4; IntAct=EBI-79464, EBI-1222766; Q92918:MAP4K1; NbExp=2; IntAct=EBI-79464, EBI-881; P45983:MAPK8; NbExp=2; IntAct=EBI-79464, EBI-286483; P08581:MET; NbExp=6; IntAct=EBI-79464, EBI-1039152; Q8WX92:NELFB; NbExp=2; IntAct=EBI-79464, EBI-347721; Q6PFX7:Nyap1 (xeno); NbExp=4; IntAct=EBI-79464, EBI-7447489; Q8BM65-4:Nyap2 (xeno); NbExp=3; IntAct=EBI-79464, EBI-7447598; P09619:PDGFRB; NbExp=19; IntAct=EBI-79464, EBI-641237; P42336:PIK3CA; NbExp=13; IntAct=EBI-79464, EBI-2116585; P16885:PLCG2; NbExp=2; IntAct=EBI-79464, EBI-617403; P49023:PXN; NbExp=2; IntAct=EBI-79464, EBI-702209; Q13905:RAPGEF1; NbExp=2; IntAct=EBI-79464, EBI-976876; P26373:RPL13; NbExp=2; IntAct=EBI-79464, EBI-356849; P19793:RXRA; NbExp=8; IntAct=EBI-79464, EBI-78598; Q9UPX8:SHANK2; NbExp=2; IntAct=EBI-79464, EBI-1570571; P29353:SHC1; NbExp=3; IntAct=EBI-79464, EBI-78835; Q96EB6:SIRT1; NbExp=3; IntAct=EBI-79464, EBI-1802965; Q07889:SOS1; NbExp=3; IntAct=EBI-79464, EBI-297487; P12931:SRC; NbExp=6; IntAct=EBI-79464, EBI-621482; P30874:SSTR2; NbExp=5; IntAct=EBI-79464, EBI-6266898; P58753:TIRAP; NbExp=3; IntAct=EBI-79464, EBI-528644; O15455:TLR3; NbExp=2; IntAct=EBI-79464, EBI-6116630; Q15661:TPSAB1; NbExp=2; IntAct=EBI-79464, EBI-1761369; Q9ULW0:TPX2; NbExp=2; IntAct=EBI-79464, EBI-1037322; Q9UKW4:VAV3; NbExp=2; IntAct=EBI-79464, EBI-297568; Q99152:VP3 (xeno); NbExp=3; IntAct=EBI-79464, EBI-1776808; Q8IUH5:ZDHHC17; NbExp=2; IntAct=EBI-9090282, EBI-524753;
PtmPhosphorylated. Tyrosine phosphorylated in response to signaling by FGFR1, FGFR2, FGFR3 and FGFR4. Phosphorylated by CSF1R. Phosphorylated by ERBB4. Phosphorylated on tyrosine residues by TEK/TIE2. Dephosphorylated by PTPRJ. Phosphorylated by PIK3CA at Ser-608; phosphorylation is stimulated by insulin and PDGF. The relevance of phosphorylation by PIK3CA is however unclear (By similarity). Phosphorylated in response to KIT and KITLG/SCF. Phosphorylated by FGR. {ECO:0000250, ECO:0000269|PubMed:15561106, ECO:0000269|PubMed:18348712, ECO:0000269|PubMed:19369195}.
PtmPolyubiquitinated in T-cells by CBLB; which does not promote proteasomal degradation but impairs association with CD28 and CD3Z upon T-cell activation. {ECO:0000269|PubMed:11087752, ECO:0000269|PubMed:11526404}.
SimilarityBelongs to the PI3K p85 subunit family. {ECO:0000305}.
SimilarityContains 1 Rho-GAP domain. {ECO:0000255|PROSITE- ProRule:PRU00172}.
SimilarityContains 1 SH3 domain. {ECO:0000255|PROSITE- ProRule:PRU00192}.
SimilarityContains 2 SH2 domains. {ECO:0000255|PROSITE- ProRule:PRU00191}.
SubunitInteracts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with PIK3R2; the interaction is dissociated in an insulin-dependent manner (By similarity). Interacts with XBP1 isoform 2; the interaction is direct and induces translocation of XBP1 isoform 2 into the nucleus in a ER stress- and/or insulin-dependent but PI3K-independent manner (PubMed:20348923). Heterodimer of a regulatory subunit PIK3R1 and a p110 catalytic subunit (PIK3CA, PIK3CB or PIK3CD). Interacts with FER. Interacts (via SH2 domain) with TEK/TIE2 (tyrosine phosphorylated). Interacts with PTK2/FAK1 (By similarity). Interacts with phosphorylated TOM1L1. Interacts with phosphorylated LIME1 upon TCR and/or BCR activation. Interacts with SOCS7. Interacts with RUFY3. Interacts (via SH2 domain) with CSF1R (tyrosine phosphorylated). Interacts with LYN (via SH3 domain); this enhances enzyme activity (By similarity). Interacts with phosphorylated LAT, LAX1 and TRAT1 upon TCR activation. Interacts with CBLB. Interacts with HIV-1 Nef to activate the Nef associated p21-activated kinase (PAK). This interaction depends on the C-terminus of both proteins and leads to increased production of HIV. Interacts with HCV NS5A. The SH2 domains interact with the YTHM motif of phosphorylated INSR in vitro. Also interacts with tyrosine-phosphorylated IGF1R in vitro. Interacts with CD28 and CD3Z upon T-cell activation. Interacts with IRS1 and phosphorylated IRS4, as well as with NISCH and HCST. Interacts with FASLG, KIT and BCR. Interacts with AXL, FGFR1, FGFR2, FGFR3 and FGFR4 (phosphorylated). Interacts with FGR and HCK. Interacts with PDGFRA (tyrosine phosphorylated) and PDGFRB (tyrosine phosphorylated). Interacts with ERBB4 (phosphorylated). Interacts with NTRK1 (phosphorylated upon ligand-binding). {ECO:0000250|UniProtKB:P23727, ECO:0000250|UniProtKB:P26450, ECO:0000250|UniProtKB:Q63787, ECO:0000269|PubMed:10086340, ECO:0000269|PubMed:10528161, ECO:0000269|PubMed:10739672, ECO:0000269|PubMed:10867024, ECO:0000269|PubMed:11087752, ECO:0000269|PubMed:11526404, ECO:0000269|PubMed:11567151, ECO:0000269|PubMed:11912194, ECO:0000269|PubMed:12009866, ECO:0000269|PubMed:12186904, ECO:0000269|PubMed:12359715, ECO:0000269|PubMed:15302586, ECO:0000269|PubMed:15488758, ECO:0000269|PubMed:18721752, ECO:0000269|PubMed:19286672, ECO:0000269|PubMed:19805105, ECO:0000269|PubMed:19807924, ECO:0000269|PubMed:20348923, ECO:0000269|PubMed:7537849, ECO:0000269|PubMed:7541045, ECO:0000269|PubMed:7692233, ECO:0000269|PubMed:8276809, ECO:0000269|PubMed:8628286, ECO:0000269|PubMed:8940081, ECO:0000269|PubMed:9038210, ECO:0000269|PubMed:9178760, ECO:0000269|PubMed:9489702, ECO:0000269|PubMed:9553137, ECO:0000269|PubMed:9687533}.
Tissue SpecificityIsoform 2 is expressed in skeletal muscle and brain, and at lower levels in kidney and cardiac muscle. Isoform 2 and isoform 4 are present in skeletal muscle (at protein level). {ECO:0000269|PubMed:8628286}.
Web ResourceName=Atlas of Genetics and Cytogenetics in Oncology and Haematology; URL="http://atlasgeneticsoncology.org/Genes/PIK3R1ID41717ch5q13.html";
  logo